 absence nephrotoxicity differential nephrotoxicity tobramycin gentamicin prospective double-blind randomized trial gentamicin tobramycin differences nephrotoxicity levels creatinine creatinine clearance beta N-acetyl-beta-D-glucosaminidase NAG indicators nephrotoxicity Forty patients criteria evaluation tobramycin received gentamicin Significant nephrotoxicity increase creatinine mg/dL group beta values patients tobramycin group gentamicin group Elevations NAG levels tobramycin group gentamicin group Elevation NAG levels congruent cases significant difference nephrotoxicity gentamicin tobramycin Elevations NAG rates similar literature significant nephrotoxicity